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Low-dose aspirin is an important therapeutic option in the secondary prevention of myocardial infarction (MI) and ischemic
stroke, basedon its unique cost-eﬀectiveness and widespread availability. In addition, based on the results of a number of large
studies, aspirin is also widely used in the primary prevention of MI. This paper provides an update of the available data to oﬀer
greater clarity regarding the risks of aspirin with respect to hemorrhagic stroke. In the secondary prevention of cardiovascular,
cerebrovascular, and ischemic events, the evidence supports that the beneﬁts of aspirin treatment signiﬁcantly outweigh the risk of
a major hemorrhage. When considering whether aspirin is appropriate, the absolute therapeutic cardiovascular beneﬁts of aspirin
must be balanced with the possible risks associated with its use, being hemorrhagic stroke. Regarding these clinical facts, normal,
COX 1 −/−,a n dC O X2−/− mice were treated with a wide range of doses of aspirin and studied by induced hemorrhagic time.
The results outlined three major conclusions: high doses of aspirin induce hemorrhage, while low doses of aspirin do not. In the
absence of COX 1, ultralow doses of aspirin produce an antihemorrhagic eﬀect notobserved withintermediate doses.The absence
of COX 2 induced a hemorrhagic eﬀect that needs further research, probably originated in compensatory phenomena.
1.Introduction
Despite more than 100 years of use, acetyl salicylic acid
(aspirin) has only been recognized for the prevention of
myocardial infarction (MI) and ischemic stroke for the
past 25 years. Over this period, based on its unique cost-
eﬀectiveness and widespread availability, the utilization of
aspirin has expanded substantially for both primary and
secondary prevention of cardiovascular events, providing
signiﬁcant insight into its safety and eﬀectiveness.
The decision as to which patients to treat must weigh the
beneﬁts of chronic aspirin therapy against the possible risks
associatedwith its use,including the risk ofintracerebraland
subarachnoid hemorrhage, the most serious risks associated
with the use of aspirin [1–7].
As the number of studies evaluating the long-term use
of aspirin has expanded, it is now possible to evaluate the
evidence in aggregate to more conclusively estimate the risk
of hemorrhagic stroke, allowing a more informative beneﬁt-
risk assessment.
The antithrombotic eﬀectiveness of aspirin is related
to its inhibition of the cyclooxygenase (COX) enzyme that
metabolizes arachidonic acid to a variety of prostanoids, in-
cluding thromboxane A2 [8]. Platelet-derived cyclooxygen-
ase-1 (COX-1) generates thromboxane A2 , a potent vaso-
constrictor and platelet agonist. The eﬀect of aspirin on
platelet COX-1 is irreversible, thus providing for once-daily
low-dose eﬀectiveness. With the inhibition of platelet COX-1
activity, there is a decrease in platelet aggregation, leading to
a reduced thromboembolic potential and a commensurate
prolonged bleeding time. Thus, it is not surprising that
the major risks associated with aspirin relate to bleeding
complications.
Ontheotherhand,aspirintreatmentmustfaceresistance
or variability in response as the cause of treatment failure,
which may be due to diﬀerent kinds of causes. A previous
publication of our laboratory has shown that ultra low
dose of aspirin induced a prothrombotic eﬀect in rats [9].
This eﬀect of ultra low dose may induce the complications
observed after aspirin discontinuation [10].2 Thrombosis
To study these events, we hypothesized that modiﬁca-
tions in the response to aspirin treatment could be due
to diﬀerent doses and an altered response to Cox. We
designed an experiment using 72 normal mice and 72
genetically modiﬁed male homozygous mice without COX 1
(COX 1 −/−) and 72 lacking COX 2 (COX 2 −/−), where we
studied Induced Hemorrhage Time (IHT).
Aspirin was used in a wide spectrum of doses including
doses 100mg/kg/bw and 1mg/kg/bw and aspirin 1/100
dilutions number 5 (Dil 5), 9 (Dil 9), and 15 (Dil 15), which
were obtained by successive 1/100 dilution. Sterilized water
was used as placebo. All drugs were injected subcutaneously
at a ﬁnal volume of 1mL/kg/BW.
2.MaterialandMethods
2.1. Animals. Normal mice from centre d’´ elevage (Depre
Saint Doulchard France) and the male homozygous
COX 1 −/− and COX 2 −/− mice purchased from Taconic
Farms Inc. (Hudson City Centre, NY, USA), were housed
separately under conditions of controlled temperature and
illumination. They were fed with standard mouse chow and
water ad libitum. Animals received care in compliance with
the European Convention of Animal Care.
2.2. Induced Hemorrhagic Time. IHT was performed 10
minutes before thrombosis induction by laser. The tail of the
mouse was immersed in water for 5 minutes at 37◦Ca n d
sectioned 6mm from the extremity, and the IHT is expressed
as the time between the tail section and the end of bleeding,
expressed in seconds.
2.3. Drugs Tested. The amounts of 1mg/mL and 100mg/mL
are obtained by dilution of a solution of Acetylsalicylate
(Aspegic, Sanoﬁ-synthelabo, France). Aspirin dilutions were
prepared as follows: 1g of pure, ﬁnely powdered aspirin was
suspended in 99mL of alcohol (70◦). After being vigorously
shaken, 1mL of this dilution was then mixed with 99mL
of distilled water and vigorously shaken (dilution 1). The
last process was repeated until obtaining desired dilutions:
4 times (dilution 5), 8 times (dilution 9), and 14 times
(dilution 15). Sterilized water (placebo) or aspirin was
subcutaneously administered at a ﬁnal volume of 1mL/kg
mouse weight. The groups were treated with placebo or
aspirin in 100mg/kg or 1mg/kg, or dilutions 5, 9, or 15.
Aspirin or the corresponding placebo was subcutaneously
administered at a ﬁnal volume of 1mL/kg rat weight.
2.4. Distribution of Groups. Normal mice and COX 1 −/−
or COX 2 −/− mice were distributed in 6 groups (n =
12/group), respectively,
group 1: placebo (sterilized water),
group 2: aspirin 100mg/kg,
group 3: aspirin 1mg/kg,
group 4: aspirin dilution 5 (Dil 5),
group 5: aspirin dilution 9 (Dil 9),
group 6: aspirin dilution 15 (Dil 15).
2.5. Statistical Analysis. Data are expressed as mean ± SD
and compared using one-way analysis of variance (ANOVA)
followed by Dunnet’s multiple comparison test. A value of
P<0.05wasconsideredassigniﬁcant.Statisticalcalculations
were performed using Graph Pad Prism version 4.00 for
Windows (http://www.graphpad.com).
3. Results
3.1. Eﬀects of Aspirin on the Induced Hemorrhagic (IHT)
in Normal Mice (Figure 1). Compared to the control group
(113.9 ± 24.64sec), aspirin administered at 100mg/kg
increases in a statistically signiﬁcant manner the THP
(363.3 ± 93.3sec). The other amounts of aspirin tested
(1mg/kg, Dil 5, Dil 9 and Dil 15) do not modify the IHT
compared to the control group (P>0.05).
3.2. Eﬀects of Aspirin on the Induced Hemorrhagic (IHT) in
COX 1 −/− Mice (Figure 2). COX 1 −/− mice control group
show an increase in the IHT (255.7±92.3sec). The amounts
of 100mg/kg, 1mg/kg, Dil 5, and Dil 9 of Aspirin do not
change signiﬁcantly this eﬀect (288.3 ± 77.0sec, 287.8 ±
79.2sec, 275.0 ±107.2sec, and 229.3 ±80.63sec, resp.).
Administered at Dil 15, Aspirin decreases in a statistically
signiﬁcant manner the IHT (164.8 ±88.96sec).
3.3. Eﬀects of Aspirin on the Induced Hemorrhagic (IHT)
in COX 2 −/− Mice (Figure 3). COX 2 −/− mice control
group show an increase in the IHT (327.3 ± 103.8sec). In
an undiﬀerentiated way, the amounts of 100mg/kg, 1mg/kg,
Dil 5, Dil 9, and Dil 15 of aspirin do not change signiﬁcantly
thiseﬀect(212.2±109.3sec,288.1±98.7sec,300.9±131.4sec,
336.5 ±77.7sec, and 245.5 ±123.9sec,resp.).
4. Discussion
Aspirin induces an irreversible inhibition of COX 1, with
a subsequent decrease in TXA2 production, in the platelet.
This eﬀect is responsible for aspirin’s antiaggregant prop-
erties which last for approximately 10 days, the lifespan of
platelets [8]. Aspirin also inhibits COX 2 but at higher doses
than required for COX 1 inhibition [11]. Indeed, it has been
reported that 100mg of aspirin is required to abolish the
production of TXA2 in normal individuals [12].
Results from this study showed a statistically signiﬁcant
prolongation in IHT in COX 1 −/− and COX 2 −/− mice,
when compared to normal mice.
If the increase in the IHT in mice COX 1 −/− can be
explained by the absence of thromboxane A2, conﬁrming its
role in the hemorrhagic events, the increase in the IHT in
COX 2 −/− mice imposes more research.
The administration of aspirin at 100mg/kg signiﬁcantly
increases the IHT in the normal mice. In fact, suppression
of platelet aggregation and prolongation of bleeding time in
presence of ASA at high doses is related to the inhibition of
metabolism of arachidonic acid to thromboxane A2, due toThrombosis 3
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Figure 1: Induced Hemorrhagic Time (expressed in seconds).
Eﬀects of aspirin in 100 or 1mg/kg or dilutions 5, 9, or 15 in
normal mice. Data expressed as mean ± SD and analyzed with
on-way ANOVA followed with Dunnet’s multiple comparison test;
n = 12/group.
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Figure 2: Induced Hemorrhagic Time (expressed in seconds).
Eﬀects of aspirin in 100 or 1mg/kg or dilutions 5, 9, or 15 in
COX 1 −/− mice. Data expressed as mean ± SD and analyzed with
on-way ANOVA followed with Dunnet’s multiple comparison test;
n = 12/group.
the irreversible acetylation of the platelet enzyme cyclooxy-
genase, when the inhibition of vascular cyclooxygenase leads
to the loss of the protective eﬀect of prostacyclin.
The eﬀect of aspirin 100mg/kg on IHT produced no
change when compared to placebo in COX 1 −/− and
COX 2 −/− mice. The absence of COX 1 or administration
of aspirin at 100mg/kg had the same eﬀect, and these eﬀects
actnotinanonsynergisticway,asbotharesupposedtowork
through a similar mechanism over platelets activities.
Explanations for this eﬀect could include compensation
in COX 1 and 2 activity, interaction between COX and NO
synthaseassuggestedbySkilletal.[13],oraneﬀectofaspirin
outside the mechanism of COX inhibition like increased NO
synthesis by the endothelial cell as suggested by Taubert et al.
[14].
Results from this study also demonstrated that the
administration of aspirin at 1mg/kg does not modify the
IHT in the normal mice. In the same way, this amount of
aspirin does not cause more increase in the IHT observed in
COX 1 −/− and COX 2 −/− mice control groups. However,
in previous studies, 1mg/kg of aspirin administered to the
rat decreased the formation of thrombi in a signiﬁcant way.
In the normal mice, the administration of aspirin at the Dil 5
and Dil 9 does not modify, compared to the control, the IHT.
In the same way, these amounts of aspirin do not modify the
increase in the IHT observed in COX 1 −/− and COX 2 −/−
mice control groups.
0
50
100
150
200
250
300
350
400
450
500
Plac 100 mg 1 mg Dil 5 Dil 9 Dil 15
(
s
e
c
o
n
d
s
)
Figure 3: Induced Hemorrhagic Time (expressed in seconds).
Eﬀects of aspirin in 100 or 1mg/kg or dilutions 5, 9, or 15 in
COX 2 −/− mice. Data expressed as mean ± SD and analyzed with
on-way ANOVA followed with Dunnet’s multiple comparison test;
n = 12/group.
In the normal mice, aspirin at the Dil 15 does not modify
the IHT compared to the control group. But, the adminis-
tration of this same high dilution of aspirin shortened in a
statistically signiﬁcant way the increase of the IHT, observed
in the control group of COX 1 −/− mice. This inhibiting
eﬀect of Dil 15 is not signiﬁcant in COX 2 −/− mice.
The above-cited results clearly show that the ultra low
dosesofaspirin studied haveastatisticallysigniﬁcanthemor-
rhagic inhibitory eﬀect.This eﬀectis achieved despite the ab-
sence of COX 1, suggesting a diﬀerent mechanism of action.
In conclusion, this study conﬁrms the hemorrhagic ac-
tion of aspirin at 100mg/kg in the absence of COX 1, and an-
tihemorrhagic eﬀect was observed, when administered at di-
lution 15.
This modifying eﬀect is very marked in the normal mice
and in COX 1 −/− mice, in other words in the presence of
the COX 2. The hemorrhagic eﬀe c to b s e r v e di nC O X2−/−
mice warrants further research.
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